|Articles|December 5, 2011

Podcast - OSO BioPharmaceuticals Kimberly K. Ray

Podcast - OSO BioPharmaceuticals Kimberly K. Ray

 

Kimberly K. Ray
Sr. Manager, Project Management,
OSO BioPharmaceuticals

With an increasing focus on containment for pharmaceutical manufacturing, active pharmaceutical ingredients (APIs) are becoming more targeted, hence more potent. Environmental, health and safety (EHS) groups push for the use of engineering controls, but the implementation of RABS and isolation technology may be an ideal solution for some pharmaceutical manufacturers; however it may not be the most efficient processing option, or the most cost effective. A risk-based approach to containment offers some alternatives. We will discuss how Oso BioPharmaceuticals has successfully implemented scientific, risk-based approach to handling hazardous compounds, how it has impacted their clients, and the reaction of regulatory bodies. OsoBio will share how implementation of this approach has affected its business as well as its processes.

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.